静止剂的使用改善了心力衰竭中的血管功能,并保留了喷射分数.
Jarred J Iacovelli1, Jeremy K Alpenglow1, Stephen M Ratchford2
1Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, United States.
Journal of applied physiology (Bethesda, Md. : 1985)
|February 22, 2024
概括
低剂量阿托瓦斯塔丁在心力衰竭患者中改善了血管内皮功能,其中保留了喷射分数 (HFpEF). 这种他类药物治疗增强了手臂动脉血管扩张,并减少了HFpEF患者的氧化应激标志物.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭与血管内皮功能受损有关.
- 基甲基谷氨基-CoA (HMG-CoA) 减少酶抑制剂 (他类药物) 可能改善血管功能.
研究的目的:
- 评估30天阿托瓦斯塔丁在HFpEF患者的周围血管功能和炎症和氧化应激的生物标志物的疗效.
主要方法:
- 一项并行,双盲,安慰剂控制的研究,涉及16名HFpEF患者 (8名他类药物,8名安慰剂).
- 评估了流媒体扩张 (FMD),持续刺激的口腔疾病 (SS-FMD),反应性高血压 (RH) 和运动高血压.
- 测量了作为脂质过氧化的标志物的麦隆迪阿尔海德 (MDA).
主要成果:
- 阿托尔瓦斯塔丁显著改善了口病和SS-FMD,表明增强了导管和微血管功能.
- 在这两组中,RH和运动高血压保持不变.
- 静止剂的使用降低了MDA水平,这是氧化损伤的标志物.
结论:
- 低剂量阿托瓦斯塔丁可以改善手臂动脉内皮依赖于HFpEF患者的血管扩张.
- 这些好处可能部分归因于氧化应激的减少.
- 在这个队列中,他类药物治疗没有改善微血管反应性或运动肌肉血流.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158


